French healthtech startup Theremia has raised €3 million to enhance drug efficacy and improve patient adherence. Eurazeo and Salica Investments are the lead investors.
- Founded in 2024 by Chloé Geoffroy and Iris Maréchal, Theremia develops AI-driven solutions to optimize drug efficacy and reduce side effects, helping pharmaceutical companies create more personalized treatments. It focuses on specific patient subgroups, especially those with neurological disorders.
- Notable organizations trust the startup, including Station F, Medicen, Entrepreneur First, Agoranov, Female Founders Fellowship, DayOne, and Deep Tech Pioneers.
Details of the deal
- The round was led by Eurazeo, a leading global investment company with €34.1 billion in AUM, offering expertise in private equity, private debt, real estate, and infrastructure, and has supported 590 companies worldwide, and London-based VC Salica Investments.
- The fresh round also saw participation from Paris-based VC Better Angle, London-based Tiny VC, London-based VC Entrepreneur First, and several angel investors.
- The startup will use the €3 million seed funding to develop its tools, which enhance drug efficacy across diverse demographics, and optimize treatments for specific patient subgroups.
